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In this special issue of Frontiers in Pharmacology, we have asked leading experts to com-
ment and review the evidence that inﬂammatory cells play a leading role in the pathological
processes underlying neurodegenerative disorders. We now seek to draw these various
observations together into a conclusion, with the hope that this will inform further work in
this area and result in the identiﬁcation of new therapeutic targets that will have a disease
modifying effect.
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INTRODUCTION
Formany years, chronic neurodegenerative disorders of the central
nervous system (CNS) were thought of in terms of primary neu-
ronal dysfunction and loss with secondary glial and inﬂammatory
responses. These responses were deﬁned by an astrogliosis and the
presence of a few activated microglia, but of late this theory has
required revision.
Microglia, which account for approximately 10% of the adult
brain cell population, were ﬁrst described by Pio Del Rio Hortega
in 1919 (McGeer and McGeer, 2012) and their identity as a dis-
crete cell population was met with great skepticism. Nevertheless,
the recognition of microglia as a distinct cell type was taken on by
Ralph van Furth who proposed that they may have some function
akin to phagocytes found in other parts of the body. However,
it was not until the late 1980s that this ﬁeld came of age when,
using the new technique of immunohistochemistry, the McGeers
showed that within the Alzheimer’s disease (AD) brain there were
large numbers of activatedHLA-DR II positivemicroglia (McGeer
et al., 1987). This paper, which struggled to ﬁnd its way into pub-
lication, has now been cited many hundreds of times and paved
the way for a whole new area of work on the glial response in
neurodegenerative disorders. This ﬁrst demonstration of class II
positive microglial cells in AD led to further discoveries of such
cells in a whole range of different neurodegenerative disorders and
with it the concept of neuroinﬂammation. The pioneering work of
the McGeers was to radically change how these diseases were seen
as they went on to show that microglia were not only intimately
bound to central inﬂammatory responses and antigen presenta-
tion, but in fact the whole innate immune system itself had a role
to play in these CNS disorders.
We now know that microglia continuously and actively survey
the CNS microenvironment (Nimmerjahn et al., 2005), although
their distribution is not uniform across the brain which may
impact on their pathogenic capacity in different disease states
(Lawson et al., 1990). They arise from the primitive myeloid prog-
enitors and enter the developing CNS during embryogenesis and
continue to be produced throughout life, sharingmany similarities
to peripheral macrophages. The original description of the phago-
cytic properties of microglia was taken to show that their primary
function was to remove dying and dead cells and by so doing pre-
vent the release of pro-inﬂammatory cytokines, chemoattractants,
and inﬁltrating T-cells. However of late,GuyBrown and colleagues
have shown that under certain conditions, activated microglia can
actually phagocytose viable neurons and synapses and that this
may be especially prominent in areas of CNS neuroinﬂamma-
tion as is seen in many, if not all, neurodegenerative disorders
(Neher et al., 2012). This would ﬁt well with their role in synaptic
pruning in normal development as well as their emerging role in
plasticity in the normal brain (Tremblay et al., 2011). In addition,
microglia have an important role in adult neurogenesis through
their ability to remove apoptotic cells and by so doing allow the
integration of those cells that survive and mature into neurons
[reviewed in Ekdahl (2012)]. Thus microglia have a repertoire of
roles throughout life in the CNS.
MICROGLIA AND ALZHEIMER’S DISEASE
An appreciable number of brain diseases seem to share the com-
mon feature of a marked glial response and in this respect the role
of microglia in AD has been particularly well studied following
on from the original observations of the McGeers (McGeer et al.,
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1987). This disorder, the most common of the chronic neurode-
generative diseases, typically presents with an evolving amnesic
syndrome and is characterized pathologically by the deposition
of extracellular beta-amyloid plaques and intracellularly by tau
tangles. The way in which these two pathologies interact with
each other to cause disease is unclear, as is how they relate to the
inﬂammation seen within the brains of patients dying with AD.
Nevertheless, it is known that inﬂammation starts early in the
disease process, probably ahead of any obvious amyloid deposi-
tion [reviewed in Politis et al. (2012)] and at post-mortem there
is a substantial inﬂammatory response especially around the Aβ
plaques. Indeed, Aβ itself can activate microglia which in turn can
phagocytose neurons, suggesting thatmicroglia are a critical deter-
minant of neuronal cell loss in this condition (Fuhrmann et al.,
2010). Neuroinﬂammation has also been linked to tau-mediated
neurodegeneration as well.
For many years, though, the role of inﬂammation in AD, whilst
being recognized as being present, was always relegated to be a
secondary or downstream event. However, the recent GWAS in
AD have shown that a number of genetic loci linked to the dis-
ease possibly code for inﬂammatory factors (Harold et al., 2009),
which implies that they may be much more intimately involved
in the actual disease process. In this respect, it is of interest to
note that systemic inﬂammation can also inﬂuence what happens
within the CNS, which has led some investigators to propose that
it may be a critical initiating factor in the genesis of disorders such
as AD, and it is through this non-CNS route that the GWAS loci
mediate their susceptibility effects (Ransohoff and Perry, 2009).
Whilst microglia responses can be thought to be detrimental
to neuronal viability and survival, it is possible that some of the
microglia responses may actually be neuroprotective by virtue of
the fact that they could help clear Aβ, remove damaged cells and
secrete a range of growth factors and anti-inﬂammatory agents
[reviewed in Solito and Sastre (2012)]. Whilst all this may be
the case in the young CNS, there is now an emerging concept
that AD results primarily from microglial senescence and a pro-
gressive breakdown of innate CNS immunity. This is because
the major function of microglia is a neuroprotective one given
their ability to phagocytose pathogens, secrete neurotrophic fac-
tors as well as dampen down free radical production and sequester
glutamate in conjunction with astrocytes. Indeed, the astrocytic
response has an equally important role in AD pathogenesis with
evidence that astrocytes and neurons can interact in a vicious cycle
of chronic, sustained, progressive neuroinﬂammation and cell
death. For example, in advanced stages of AD, it has been shown
that TRAIL secreted from astrocytes binds to death receptors on
neurons to trigger apoptosis (Li et al., 2011).
All of this complexity of action of inﬂammatory cells in an
aging CNS presents a challenge in knowing how best to target
them therapeutically in AD.
MICROGLIA AND PARKINSON’S DISEASE
Parkinson’s disease (PD) has long been described clinically
through its motor manifestations of a resting tremor, rigidity,
and bradykinesia and, pathologically, by the formation of alpha
synuclein positive Lewy bodies in the substantia nigra with the
loss of the nigrostriatal dopaminergic projection. However, it is
now clear that the pathology, and the clinical features of PD, are
much more extensive and that the disease may even start outside
the CNS (Ferrer et al., 2011). This change in our understanding
of the extent and pattern of evolution of PD pathology has led
to a re-examination of the pathogenic process and with this the
potential role for inﬂammation and microglia, as ﬁrst suggested
by McGeer et al. (1988a) as early as 1988.
Several studies have now shown that microglial activation and
elevated levels of inﬂammatory cytokines accompany neurode-
generation in PD patients (McGeer et al., 1988b; Mogi et al., 1994,
1995a,b; Banati et al., 1998). For example, Langston et al. (1999)
in the post-mortem analysis of MPTP intoxicated patients and
Brownell et al. (1999) in primates exposed to the same toxin,
pointed to the possibility of an inﬂammatory and glial response
in MPTP induced nigral cell death [also see review by McGeer
et al. (2001)]. Subsequent studies have conﬁrmed that activated
microglia can be seen in the brains of patients with idiopathic PD
both using PET imaging [reviewed in Politis et al. (2012)] and
pathologically (reviewed in Huang and Halliday (2012)). These
changes occur early in the disease course and thereafter remain sta-
ble, which suggests that they may be an important initiating event
(Ouchi et al., 2005). In this respect, it has now been shown that in
animal models of PD, dopaminergic cell loss can be induced solely
by inﬂammatory insults (e.g., Lipopolysaccharide, LPS; Cicchetti
et al., 2009a) and that in more traditional neurotoxin induced ani-
mal models of PD, inﬂammation may be necessary for the full
expression of the lesion (e.g., Drouin-Ouellet et al., 2011). Fur-
thermore, it has been shown that α- synuclein itself can directly
activate microglia (Zhang et al., 2005), and that many of the gene
products from the mendelian forms of PD, not only have a role
in the intracellular handling of PD related proteins, but also in
modulating innate immune signaling (Huang andHalliday, 2012).
This sits well with the recent genetic studies linking PD to HLA
(Hamza et al., 2010; Saiki et al., 2010). Finally it isworthnoting that
activated microglial cells in PD are predominantly found in prox-
imity to a key sign of aging namely free neuromelanin (McGeer
et al., 1988b) – again highlighting the complex interplay between
microglia, disease processes, and an aging CNS.
Other inﬂammatory cells, such as astrocytes, may also be
important in PD not only by virtue of their known ability to
support normal neuronal function but also through a role inmain-
taining the integrity of the blood brain barrier (BBB; Halliday and
Stevens, 2011). This may be especially important as abnormali-
ties in this structure (namely the BBB) could allow other parts of
the immune system to gain access to the CNS and by so doing
contribute to the pathology seen in PD (Kortekaas et al., 2005).
MICROGLIA AND HUNTINGTON’S DISEASE
Huntington’s disease (HD) is a rare autosomal dominant disor-
der characterized by motor, cognitive, and psychiatric problems
with extensive pathology across the CNS. Driven by this dominant
genetic mutation in the huntingtin gene, the neuropathological
signs of HD are visible in many structures of the CNS, but pre-
dominantly within the striatum and cortex from an early stage of
disease. This prominent neuronal loss is accompanied by protein
aggregates composed of the mutated form of the huntingtin pro-
tein and with this there is signiﬁcant activation of microglia (Sapp
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et al., 2001). This activation has been shown in both premanifest
(Tai et al., 2007) and manifest HD patients (Sapp et al., 2001) and
there appears to be a correlation between the level of microglial
activation and disease severity (Pavese et al., 2006), all of which
suggests that the microglia are intimately involved in the disease
process in HD.
There is now emerging evidence that the ubiquitous expres-
sion of the mutant huntingtin protein affects the function of cells
outside the CNS. In particular, the mutant huntingtin protein
interactswith the immune systemwith accumulating evidence that
changes in this system may critically contribute to the pathology
of HD. However, the nature of this contribution remains unclear,
to the extent that it is not even knownwhether the immune system
plays a beneﬁcial or detrimental role in HD patients (Soulet and
Cicchetti, 2011). What is clear is that analysis of blood samples
from HD patients shows abnormal release of pro-inﬂammatory
cytokines in early stages of the disease (Bjorkqvist et al., 2008).
The astrocytic response in HD is substantial and in fact deﬁned
early descriptions of the pathology. Indeed the original grading
system of striatal atrophy and disease severity by Vonsattel et al.
(1985) used this response. This work also highlighted how the
astrocytic response follows neuronal loss such that the striking
striatal atrophy following a dorso-ventral pattern is mirrored by
the intensity of the astrocytosis.
As in theotherneurodegenerative conditionswehavediscussed,
the glia are not passive bystanders to the disease process, but seem
to be an integral part of the pathological process from the time of
disease onset.
MICROGLIA AND MOTORNEURON DISEASE
Motorneuron disease covers a range of disorders all of which are
characterized by the loss of motorneurons (MNs), and the extent
to which this selectively targets the upper or lower MN deﬁnes the
disease type, e.g., primary lateral sclerosis (PLS) for a pure upper
motor neuron (UMN) disorder whilst spinal muscular atrophy
(SMA) singles out the lower motorneurons (LMNs). However, the
commonest type involves both UMN and LMNs and is termed
amyotrophic lateral sclerosis (ALS), and whilst there are known
genetic forms of this disorder, the vast majority are sporadic in
nature (Talbot, 2011). Nevertheless, the rare genetic forms of ALS,
especially those withmutations in SOD1, have been used tomodel
the disease in the laboratory and of late this has led to studieswhere
the mutant gene has been differentially expressed in various cel-
lular compartments within the CNS. These studies have clearly
shown that the effects of the mutant gene in non-neuronal cells
is not insigniﬁcant, and coupled to the pathological ﬁndings in
patients dying with ALS, has suggested that the disorder is one
that is critically dependent on events in neurons, astrocytes, and
microglia (Phani et al, submitted).
Within the MN itself, many pathogenic pathways, which com-
promise that cell – subsequently leading todysfunction anddeath –
have been postulated (Ince et al., 2011). These pathways involve the
production of abnormal reactive oxidative species (ROS) which
in turn compromises mitochondrial function, energy production,
and cell integrity. This abnormal production of ROS is enhanced
in SOD mutant cells and can further be exacerbated by excessive
glutamate stimulation of theMNs and calcium inﬂux. These latter
processes may be in part mediated by abnormal glutamate han-
dling by astrocytes, as further supported by studies demonstrating
the beneﬁcial effects of glial cell grafts in transgenic models of ALS
(Lepore et al., 2008).
In addition, whilst the astrocyte-neuron interactions may be a
critical component in the disease process, it is also known that in
the brains of patients dying with ALS there is a marked microglial
response. As is common to other neurodegenerative disorders, the
question arises as to where this reaction lies in the causal cas-
cade of pathogenic events and whether this changes over time. In
this respect, there is evidence in animal models that minocycline
can have deleterious effects on microglia and astrocytes once the
disease has begun (Keller et al., 2011), which is in line with a clin-
ical study of this drug in ALS showing that it was ineffective and
even harmful (Gordon et al., 2007). As such, it is likely that the
microglia, as with the astrocytes, do play a role in the loss of MNs
in ALS, although the extent to which selectively targeting them
therapeutically will truly change the disease course is less clear.
What is clear however, is that in ALS, the disease is not localized to
the motorneuronal compartment and as such, strategies designed
around studying patient speciﬁc induced pluripotent stem cell
derived MNs may only give partial answers. This is especially true
if such assays are being used for patient selective drug screens
(Ebert et al., 2009).
INFLAMMATORY CELL TARGETING FOR FUTURE
THERAPEUTIC APPROACHES TO NEURODEGENERATIVE
DISORDERS
Initial views on the role of microglia suggested that these cells were
simply there to scavenge up debris and dead cells, while astrocytes
fulﬁlled some supportive role in the CNS. However, microglia are
now recognized to have a complex array of supportive anddestruc-
tive roles in the CNS and that the balance between the two may
be critical in driving some aspects of disease processes. Astrocytes
are now seen as being fundamental in shaping and maintaining
the developing and mature CNS, including a role in adult neuro-
genesis, axonal regeneration, and the BBB. The dynamic interplay
between all of these different CNS compartments is becoming
more evident, such that some neurodegenerative disorders of the
CNS may have a pathology as much in the glial cells as in the neu-
rons themselves. This all means that understanding what happens
in disease states is far more complex than originally conceived and
that targeting each element of the interaction may be the route by
which true disease modiﬁcation can be achieved.
In this special issue of Frontiers in Pharmacology we have
repeatedly seen how the glia, immune response, and neurons
interact to drive disease, and that our abilities to more accurately
deﬁne and follow this in vivo has enabled us to better under-
stand the temporal relationships that exist between these cellular
players and when and how they can best be modulated for ther-
apeutic beneﬁt. Indeed, our capacity to better visualize the glial
cells in patients with neurodegenerative disorders especially with
respect to microglia is well covered by Politis et al. (2012). This is
particularly important given the limitations of animal models of
neurodegeneration which includes the fact that they often model
disease using a transgenic approach, even though the commonest
neurodegenerative disorders (AD and PD) are largely sporadic in
www.frontiersin.org May 2012 | Volume 3 | Article 95 | 3
Barker and Cicchetti The glial response in disorders of CNS
nature. In addition, these animals typically develop disease over
weeks and months when in patients they evolve over months or
years, and thus short acute therapies in the laboratory may not
be relevant to the clinic. Finally, our capacity to better deﬁne the
heterogeneity of patient populations has meant that the therapeu-
tic idea that “one size ﬁts all” is no longer tenable, and that disease
processesmay followvery different trajectories in different patients
and as such require completely different therapeutic approaches
(see, e.g.,Williams-Gray et al., 2009).A point reinforced by the het-
erogeneity of glial responses as a function of age and disease state.
As we move toward an era of ever more sophisticated thera-
peutic agents, our ability to better understand networks of disease
pathogenesis will become increasingly important as our capacity
to dissect the role of each component will be critical to the success
of any such therapy. This is perhaps best shown in the world of
cellular transplants for HD, where simply delivering a cell replace-
ment therapy to a diseased brain may not be useful in itself, not
because there is anything intrinsically wrong with replacing dys-
functional and lost neurons, but because the necessary support
for those cells is no longer there and may even be replaced by
a hostile environment (Cicchetti et al., 2009b, 2011). It has even
been proposed and demonstrated that in some animal models of
motorneuron disease, transplanting glial cells is better than trying
to replace theMNs per se, as the former have a more critical role in
disease pathogenesis through their handling of glutamate (Lepore
et al., 2008).
In conclusion, there is now a growing body of evidence from
many different sources demonstrating that glial and inﬂammatory
responses are central to these diseases – this includes ﬁndings
from epidemiological studies looking at anti-inﬂammatory drugs
and the risk of PD and AD; the GWAS in AD and PD; patho-
logical and imaging studies in patients as well as the study of
peripheral markers of inﬂammation [e.g., in HD – reviewed
in Wild et al. (2008)]. All of this makes for a very persuasive
role for the glia and inﬂammation in chronic neurodegenera-
tive disorders of the CNS, which will set the scene for a whole
new approach to disease modifying therapeutics for a group of
disorders that will become increasingly more common as the
population ages. Exactly what form these agents will take is unre-
solved but may involve using drugs that are already in clinical
use such as minocycline and non-steroidal anti-inﬂammatories
(NSAIs). Indeed, the use of anti-inﬂammatory agents for treating
AD has long been considered, outside of the amyloid immuniza-
tion approach (Menendez-Gonzalez et al., 2011). Their efﬁcacy has
yet to be proven especially with respect to the commonly available
NSAIs which appear to be much less effective in controlling the
activation of aged, as compared to young microglia and are likely
to be too wide-spectrum thereby suppressing both the detrimen-
tal (e.g., pro-inﬂammatory cytokines, oxidative stress, etc.) and
beneﬁcial roles (e.g., pro-repair processes, phagocytosis, and neu-
roprotection) of the immune cells (Soulet and Cicchetti, 2011).
Thus selecting the right agent in the right aged patient group at
the right stage of their disease will be critical, and as our under-
standing of the role of microglia, astrocytes and other related cells
evolves, and how they relate to each other, so will our capacity to
target them in disease settings.
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